Previous close | 2.0100 |
Open | 1.9900 |
Bid | 1.8700 x 900 |
Ask | 1.9600 x 1000 |
Day's range | 1.8701 - 2.0400 |
52-week range | 1.3300 - 3.2900 |
Volume | |
Avg. volume | 331,596 |
Market cap | 159.501M |
Beta (5Y monthly) | 1.36 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.2600 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.60 |
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System. PPMC, part of the University of Pennsylvania Health System, renowned for advanced clinical research, innovation, and compassionate patient care, stands at the fore
Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.
Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.